Tango Therapeutics reports 92% ORR from vopimetostat plus daraxonrasib combo in pancreatic cancer, plans Phase 3 study later this year.
Will 2026 be remembered as the year when pancreatic cancer finally became treatable?
Following Revolution Medicines’ smashing success at the annual American Society of Clinical …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Tango data add to growing momentum for pancreatic cancer drugs
Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Why Is Tango Therapeutics Stock Soaring Monday? - Tango Therapeutics (NASDAQ:TNGX)
Vopimetostat-daraxonrasib combo ‘extremely encouraging’ in metastatic pancreatic cancer
Does Revolution Medicines' pancreatic cancer drug have even greater potential?
In Fight Against Pancreatic Cancer, Daraxonrasib Is Rare Sign Of Hope
What RevMed's pancreatic cancer drug meant for one patient
For pancreatic cancer patients, an exciting drug can feel out of reach
Landmark pancreatic cancer treatment paves way for targeting other tricky tumors
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what…
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an…
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically…
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
